Cost-effectiveness of disease-modifying therapy for multiple sclerosis
Neurol 77:355-363, Noyes, K.,et al, 2011
Disease-Modifying Drugs for Relapsing-Remitting Multiple Sclerosis and Future Directions for Multiple Sclerosis Therapeutics
Arch Neurol 56:1079-1084, Rudick,R.A., 1999
Glatiramer Acetate for Relapsing Multiple Sclerosis
The Medical Letter 39:61-62, , 1997
Role of Brain Biopsy in the Management of Focal Brain Lesions in HIV-Infected Patients
Neurol 54:993-997, Antinori,A.,et al, 2000
Population Based Cost Utility Study of Interferon Beta-1b in Secondary Progressive Multiple Sclerosis
BMJ 319:1529-1533, Forbes,R.B.,et al, 1999
Evaluation and Management of Intracranial Mass Lesions in AIDS
Rpt of Quality Stnds Subcomm of the AAN, Neurol 50:21-261998., , 1998
HIV-Protease Inhibitors
NEJM 338:1281-1292, Flexner,C., 1998
HIV-1 Protease Inhibitors
JAMA 227:145-149, Deeks,S.J.,et al, 1997
HIV Infection-1
BMJ 314:487-491, 579-5831997., Cohn,J.A., 1997
The Impact of Neurologic Disease on Hospitalizations Related to HIV Infection in Maryland, 1991-1992
Arch Neurol 54:846-852, DalPan,G.J.,et al, 1997
The Quality-of-Life Effects of Interferon Beta-1b in MS
Arch Neurol 54:1475-1480, Schwartz,C.E.,et al, 1997
Interferon Beta in Multiple Sclerosis
BMJ 313:1159, 1157, 1195996., Richards,R.G., 1996
Management Protocol for an Enhancing Cerebral Lesion in HIV Infection
Conn Medicine 60:649-651, Finelli,P.F., 1996
Electroencephalography
JNNP 57:1308-1319, Binnie,C.D.&Prior,P.F., 1994